Hepatitis C; Chronic Clinical Trials

A listing of Hepatitis C; Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 36 clinical trials
Featured trial
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

aplastic anemia
myelodysplastic syndrome (mds)
myelodysplastic syndromes
anemia studies
  • 22 Dec, 2020
  • 1 location
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV

  • 04 Jun, 2022
  • 36 locations
Liver Test Study of Using JKB-122 in HCV-Positive Patients

The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or relapsed from prior interferon-based therapies (pegylated or standard) either alone or in combination with …

  • 07 Nov, 2020
  • 5 locations
Therapeutic Hepatitis C Virus Vaccine

GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax) in chronic HCV patients.

  • 06 Oct, 2021
  • 1 location
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.

  • 09 Sep, 2021
  • 2 locations
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs (TEMPO)

This project aims to evaluate two strategies of Hepatitis C virus (HCV) testing compared to standard of care among people who inject drugs at needle and syringe program (NSP) services in Australia, to see if it can improve the number of people who start treatment following an HCV diagnosis: HCV …

Accepts healthy volunteers
  • 04 Oct, 2022
  • 2 locations
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C

alpha fetoprotein
antiviral drugs
chronic hepatitis
  • 24 Feb, 2022
  • 1 location
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (STORC)

This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy. Treatment will be initiated during the second or

  • 06 May, 2022
  • 1 location
Evaluation of Prolonged-release Pirfenidone in Patients With Viral C Hepatitis, With Sustained Viral Response and Advanced Residual Liver Fibrosis. Potential Role of Epigenetics to Understand Therapeutic Changes (MINERVA).

Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS). PFD effects are mediated in part through inhibition of TGFβ, TNFα, IL-1 and IL-6, along with NFκB activation down-regulation causing reduced TNFα …

  • 16 Oct, 2022
  • 1 location
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

complications of liver disease after cure of hepatitis C infection. Eligibility Adults 18 years and older infected with chronic hepatitis C virus who were never treated or

glycosylated hemoglobin
liver cancer
hemoglobin a1c
hcv genotype
  • 07 Oct, 2022
  • 1 location